Interesting abstracts.
From my days of very high optimism with RVX and then Zenith to my current much more tempered yet positive attitude I have a few observations (misguided or not) and questions.
- The study of epigenetics does not seem to generate a very high profile (e.g. unlike CRISPR - gene splicing).
- From what I know there are there are no clinical successes in epigenetics in humans to date.
- Cancer(s) seem(s) to have attracted some degree of epigenetic research and results are ???????
- Independent academic scientists are now experimenting with and publishing articles about apabetalone and the retinal and MD results seem to show promise.
- Apabetalone seems to have applications in a number of indications...CKD, DM, etc.
- I have never seen any feedback from any of the scientifc conferences regarding apabetalone and/or Zenith. Perhaps I should not expect feedback.
- RVX and Zenith seem to have become more insular for whatever reasons.
- The FDA approval for testing apabetalone did not create any level of profile in the media. I wonder why RVX would not have leveraged this with the press as a Canadian success (of sorts).
Apologies for my rambling. I remain enthused about RVX and Zenith and I wonder if they are so far advanced vs anyone else in the field it has created a credibility gap. The share price of $1.40 baffles me.
It does not appear that the scientific community is lining up behind epigenetics.
GLTA
Toinv